Gene Therapy Maintains Efficacy in Hemophilia B Out to 5 Years

(MedPage Today) — ORLANDO — Patients with hemophilia B continued to experience low annualized bleeding rates and stable endogenous factor IX expression 5 years after a single infusion of etranacogene dezaparvovec (Hemgenix), the final analysis…

Source link : https://www.medpagetoday.com/meetingcoverage/ashhematology/118932

Author :

Publish date : 2025-12-10 17:18:00

Copyright for syndicated content belongs to the linked Source.

M	T	W	T	F	S	S
						1
2	3	4	5	6	7	8
9	10	11	12	13	14	15
16	17	18	19	20	21	22
23	24	25	26	27	28

Gene Therapy Maintains Efficacy in Hemophilia B Out to 5 Years

FDA Opens Safety Review of Injectable RSV Drugs Approved for Babies and Toddlers

Last minute offer may avert next week’s doctor strike

Related Posts

Will AI Replace Physicians? Can Prior Auth Be Fixed? A Q&A With HHS’s Health IT Czar

Make the Diagnosis: What’s this Rash, and Is Her Family History Relevant?

HHS’s Vax Injury AI; FDA Official Faked Divorce? Texas Abortion Guidance

Study: SIGLEC-1 Tracks Lupus Response to Anifrolumab

The failure of ecosystem services: Why putting a price tag on nature hasn’t worked

First UK-Manufactured mRNA Vaccine Approved

Will AI Replace Physicians? Can Prior Auth Be Fixed? A Q&A With HHS’s Health IT Czar

Make the Diagnosis: What’s this Rash, and Is Her Family History Relevant?

HHS’s Vax Injury AI; FDA Official Faked Divorce? Texas Abortion Guidance

Study: SIGLEC-1 Tracks Lupus Response to Anifrolumab

The failure of ecosystem services: Why putting a price tag on nature hasn’t worked

First UK-Manufactured mRNA Vaccine Approved

Trump Administration Plans to Hold Back Grant Money for Some Democratic-Led States

FDA Refuses Application for New mRNA Flu Vaccine, Moderna Says

Categories

Archives